Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
暂无分享,去创建一个
Maryse Lapeyre-Mestre | M. Lapeyre-Mestre | J. Montastruc | Jean-Louis Montastruc | P. Olivier | Stephanie Berthet | Pascale Olivier | Stéphanie Berthet
[1] F. McAlister,et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.
[2] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[3] S. Nissen,et al. An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality , 2010 .
[4] M. Lapeyre-Mestre,et al. Non‐steroidal anti‐inflammatory drug‐related hepatic damage in France and Spain: analysis from national spontaneous reporting systems , 2006, Fundamental & clinical pharmacology.
[5] D. Hosmer,et al. A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.
[6] Bernard Bégaud,et al. Rates of spontaneous reporting of adverse drug reactions in France. , 2002, JAMA.
[7] P. Raskin,et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. , 2001, Diabetes care.
[8] A. Fagot-Campagna,et al. French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. , 2008, Diabetes & metabolism.
[9] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[10] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[11] M. Lapeyre-Mestre,et al. Prise en charge thérapeutique des patients diabétiques en France : Apport de la Banque Nationale de Pharmacovigilance , 2007 .
[12] Tara Gomes,et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. , 2007, JAMA.
[13] S. Nissen,et al. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.
[14] M. Lapeyre-Mestre,et al. Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs , 2003, Clinical neuropharmacology.
[15] Alfonso T. Perez,et al. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone , 2005, Diabetes, obesity & metabolism.
[16] P. Lurie,et al. Case series of liver failure associated with rosiglitazone and pioglitazone , 2009, Pharmacoepidemiology and drug safety.
[17] K. Belton,et al. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union , 1997, European Journal of Clinical Pharmacology.
[18] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[19] F. Schmidt. Meta-Analysis , 2008 .
[20] B Bégaud,et al. Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .
[21] C. Furberg,et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.
[22] Nancee V. Niemeyer,et al. Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.
[23] Rita Ouellet-Hellstrom,et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.
[24] J Jouglard,et al. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. , 1985, Therapie.
[25] G. Oster,et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.
[26] Frantz Thiessard,et al. Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986—2001) , 2005, Drug safety.
[27] I. Edwards,et al. Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.
[28] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[29] C. Furberg,et al. Thiazolidinediones and Heart Failure , 2007, Diabetes Care.